Work

Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling

Year: 2025

Type: erratum

Abstract: has been revised, including updated immunostaining images and corresponding data for Ki67-and CD31-positive cells in both the control and raloxifene-treated groups.Following Editor approval, Figure 4, as well as sections 2.8 and 3.8 of the article, have been updated accordingly.These corrections do not affect the overall conclusions of the article.Correction to: Cellular Oncology (2020) 44:167-177 h t t p s : / / d o i . o r g / 1 0 . 1 0 0 7 / s 1 3 4 0 2 -0 2 0 -0 0 5 5 9 -9Following the publication of this article it was noted that an incorrect immunostaining image for CD31-positive cells in the raloxifene-treated group was shown in panel 'e' of Figure 4.In the course of correcting this error, the entire Figure 4 The original article can be found online at h t t p s : / / d o i . o r g / 1 0 . 1 0 0 7 / s 1 3 4 0 2 -0 2 0 -0 0 5 5 9 -9.

Source: Cellular Oncology

DOI: 10.1007/s13402-025-01128-8